ArticleClinical proteomics2025
Integrating multimodal data to predict the progression of hormone-sensitive prostate cancer.
Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Identifying the population at risk of rapid progression from hormone-sensitive prostate cancer (HSPC) to lethal castration-resistant prostate cancer (CRPC) is a challenge. This work has highlighted important prognostic insights based on proteomics data, magnetic resonance imaging (MRI) and histopathological specimens. We retrospectively developed a multi-omics-based model based on 77 patients with HSPC. In order to identify the features related to survival time under each mode, we used the Boruta algorithm for feature screening. In order to demonstrate the effectiveness of our selected features, we used six machine learning methods to validate the classification of the selected features for each mode. A total of 63 proteome signatures, 60 HE signatures, 56 T2WI signatures, and 54 ADC signatures were identified as features related to the speed of HSPC progression. Ultimately, 30 multi-omics-based features were determined by the least absolute shrinkage and selection operator (LASSO) method and multivariate cox regression. In order to stratify patients with significant disparities in progress, a nomogram model was developed, of which the C-index was 0.906. Accordingly, the developed model could help identify patients who are at a high risk of rapid CRPC progression, and aid clinicians in guiding personalized clinical management and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.